Beamr video compression achieves up to 50% improvement for AVs
Guardian Pharmacy Services , Inc. (NYSE:GRDN), a retail drug store chain with a market capitalization of $1.62 billion, announced the results of its Annual Meeting held on May 9, 2025, in a recent SEC filing. The company, which has delivered an impressive 60% return to shareholders over the past year according to InvestingPro data, disclosed the outcomes of the stockholder votes on two key proposals.
Proposal 1 concerned the election of Class I directors to the company’s Board of Directors. Three nominees, David Morris, Mary Sue Patchett, and Thomas Salentine, Jr., were elected to serve until the 2028 Annual Meeting. Morris received 39,883,462 votes for and 5,316,005 votes withheld, with 485,295 broker non-votes. Patchett garnered 43,261,759 votes for, 1,937,708 withheld, and an identical number of broker non-votes. Salentine had 39,781,623 votes for, 5,417,844 votes withheld, and 485,295 broker non-votes.
Proposal 2 addressed the ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025. The proposal passed with a significant majority of 45,640,998 votes for, 43,710 against, and only 54 abstentions.
This SEC filing also confirmed the company’s commitment to transparency and governance, with the board’s composition reflecting the votes of its shareholders. The document was signed by David K. Morris, the Executive Vice President and Chief Financial Officer of Guardian Pharmacy Services, Inc., ensuring the filing met the requirements of the Securities Exchange Act of 1934. With revenue growing at 17.4% and analysts expecting profitability this year, investors can access deeper insights through the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks.
The information provided in this article is based on the company’s SEC filing and is intended to inform the public and shareholders about the recent developments within the company. Investors should note that Guardian operates with moderate debt levels and is currently trading above its Fair Value according to InvestingPro’s analysis, with the next earnings report scheduled for May 12, 2025.
In other recent news, Guardian Pharmacy Services Inc. reported a strong performance in the fourth quarter of 2024, with a 20% increase in revenue, reaching $339 million. The company’s adjusted EBITDA also saw a significant rise of 30%, totaling $26 million for the quarter. For the full year, Guardian’s revenue increased by 17.4% to $1.228 billion, while adjusted EBITDA grew 19% to $91 million. The company expanded its operations by adding nine new pharmacy locations and completing two acquisitions, contributing to its robust growth strategy. Looking forward, Guardian projects its 2025 revenue to be between $1.330 billion and $1.350 billion, with an expected adjusted EBITDA of $97 million to $101 million. The firm anticipates maintaining a high single-digit organic growth rate, bolstered by mergers and acquisitions. Despite potential challenges from the Inflation Reduction Act, Guardian remains confident in mitigating these impacts. Analysts from firms like Raymond (NSE:RYMD) James and Truist have engaged with Guardian, indicating ongoing interest in its strategic initiatives and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.